Drugmaker AbbVie said it will buy Pharmacyclics for about $21 billion to boost its oncology drugs pipeline.» Read More
Emergency rooms are no less crowded since Obamacare started, Trevor Fetter, CEO of hospital operator Tenet Healthcare, tells CNBC.
Pfizer, one of the world's biggest drugs firms, may have had a $106 billion takeover bid for rival AstraZeneca rejected, but analysts expect it to get its way in the end.
Bayer will acquire the consumer care business of U.S.-based Merck & Co for $14.2 billion in cash, the company said in a statement Tuesday.
AstraZeneca, the pharmaceutical company fighting off repeated approaches from larger rival Pfizer, has boosted its defense against the raid.
As the federal government is trying to provide enough oversight on its credit card program, it's struggling to do so and it is starting to cost money.
The Greenlight Capital co-founder called Athenahealth a "bubble" stock, which sent the shares plummeting after hours.
The FDA said that people should use daily aspirin therapy only after assessing the benefits and risks.
The FBI is investigating Oregon's disastrous Obamacare exchange, possibly in connection the use of federal funds to build that insurance marketplace.
Britain's opposition Labour party has called for an inquiry into a potential takeover of British firm AstraZeneca by U.S. drugmaker Pfizer.
Pfizer reported revenues well below Wall Street expectations, hurt by falling sales of generic medicines it calls established pharmaceuticals.
Nnew research suggests that, even without a match, some popular e-cigarettes get so hot that they, too, can produce a handful of the carcinogens found in cigarettes and at similar levels. The NYT reports.
Employees at Pfizer Inc's U.S. research centers may want to dust off their resumes if the company's proposed acquisition of Britain's AstraZeneca comes to fruition.
The number of nonpaying Obamacare enrollees is going to be huge, says Jake Novak.
Some states whose governors were hostile toward Obamacare exceeded enrollment projections, while some big boosters fell short.
Pfizer CEO Ian Read recently met with U.K.-based investors to discuss a second bid for AstraZeneca, valuing the firm at $106 billion, sources said.
HHS Secretary Kathleen Sebelius says the enrollment tally exceeded expectations, and "demonstrated brisk demand for quality, affordable coverage."
The WHO’s recent warning about germs resistant to antibiotics has raised questions about what pharma companies are doing to fight this.
A report released Wednesday said one-third of people who signed up for health insurance through new federal exchanges hadn't paid their first month's premium.
As rivals assessed what Pfizer's play for AstraZeneca could mean for the industry, one aspect touched nearly everyone: What it could mean for a U.S. tax loophole.
Danish insulin manufacturer has posted 15 percent growth in first-quarter operating profit but cut its sales outlook for 2014.
Get the best of CNBC in your inbox